Results 351 to 360 of about 749,263 (385)
Some of the next articles are maybe not open access.
ARHGEF26: a new player in vascular endothelial growth factor receptor 2 trafficking
Cardiovascular Research, 2022International ...
Anne-Clémence Vion, Gervaise Loirand
openaire +3 more sources
Brain Research, 2004
In this study, for the first time, we investigated about the localization of VEGF-A, VEGFR-2 and Ang-2 in the choroid plexuses of the adult mouse by Western blot and immunohistochemistry. Results showed that VEGF-A stained epithelial cells, while anti-VEGFR-2 and -Ang-2 antibodies stained endothelial cells.
Nico, Beatrice +6 more
openaire +3 more sources
In this study, for the first time, we investigated about the localization of VEGF-A, VEGFR-2 and Ang-2 in the choroid plexuses of the adult mouse by Western blot and immunohistochemistry. Results showed that VEGF-A stained epithelial cells, while anti-VEGFR-2 and -Ang-2 antibodies stained endothelial cells.
Nico, Beatrice +6 more
openaire +3 more sources
Critical Care Medicine, 2005
Vascular endothelial growth factor (VEGF) regulates vascular proliferation and causes vasodilation. In the pulmonary circulation, the vasorelaxing effect of VEGF has been attributed to nitric oxide, whereas in other vascular beds, prostacyclin and other mechanisms are also involved. This vascular effect follows binding to two receptors, VEGF receptor 1
Annie, Janvier +3 more
openaire +2 more sources
Vascular endothelial growth factor (VEGF) regulates vascular proliferation and causes vasodilation. In the pulmonary circulation, the vasorelaxing effect of VEGF has been attributed to nitric oxide, whereas in other vascular beds, prostacyclin and other mechanisms are also involved. This vascular effect follows binding to two receptors, VEGF receptor 1
Annie, Janvier +3 more
openaire +2 more sources
Abstract 5767: Vascular endothelial growth factor receptor 2 targeted photoimmunotherapy
Cancer Research, 2018Abstract Background Photoimmunotherapy (PIT) is a new class of molecular targeted cancer theranostics, which employs monoclonal antibody (mAb) conjugated to a photosensitizer, IR700, that is activated by focal near-infrared (NIR) light irradiation leading to necrotic cell death by cell membrane rapture where mAb-IR700 ...
Makoto Mitsunaga +2 more
openaire +1 more source
Clinical Laboratory, 2019
Biomarkers for early diagnosis and follow-up of cancers are still underutilized in clinical management. Thus, seeking new biomarkers with better sensitivity and specificity is still a challenge. VEGF, VEGFR2, and OPN are newly emerging biomarkers with clinical potential.ELISA was used to analyze serum VEGF, VEGFR2, and OPN from 75 gastrointestinal ...
Liejun, Jiang +6 more
openaire +2 more sources
Biomarkers for early diagnosis and follow-up of cancers are still underutilized in clinical management. Thus, seeking new biomarkers with better sensitivity and specificity is still a challenge. VEGF, VEGFR2, and OPN are newly emerging biomarkers with clinical potential.ELISA was used to analyze serum VEGF, VEGFR2, and OPN from 75 gastrointestinal ...
Liejun, Jiang +6 more
openaire +2 more sources
A new PET tracer specific for vascular endothelial growth factor receptor 2
European Journal of Nuclear Medicine and Molecular Imaging, 2007Noninvasive positron emission tomography (PET) imaging of vascular endothelial growth factor receptor 2 (VEGFR-2) expression could be a valuable tool for evaluation of patients with a variety of malignancies, and particularly for monitoring those undergoing antiangiogenic therapies that block VEGF/VEGFR-2 function.
Hui, Wang +6 more
openaire +2 more sources
Cancer treatment and survivorship statistics, 2022
Ca-A Cancer Journal for Clinicians, 2022Kimberly D Miller +2 more
exaly